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Background: Patisiran, an RNA interference therapeutic, has demonstrated robust reduction of wild-type and
mutant transthyretin protein and was able to improve polyneuropathy and quality of life following 18 months of
treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. In this 24-month Phase II open-
label extension study, we evaluated the effects of patisiran treatment (0.3 mg/kg intravenously every 3 weeks) on
safety, serum transthyretin levels, and clinical parameters. Efficacy assessments included modified Neuropathy
Impairment Score +7 (mNIS+7) and multiple disease-relevant measures. Cardiac assessments were performed in a
pre-specified cardiac subgroup.
Results: Twenty-seven patients entered this study, including 12 (44%) with ambulation difficulties due to their
neuropathy and 11 (41%) who met criteria for the cardiac subgroup. During treatment, the majority of adverse
events were mild/moderate in severity; there were no drug-related adverse events leading to treatment
discontinuation. The most common drug-related adverse events were flushing and infusion-related reactions (22%
each). Patisiran resulted in rapid, robust (~ 82%), and sustained reduction of mean transthyretin levels over
24 months. A mean 6.95-point decrease (improvement) in mNIS+7 from baseline was observed at 24 months.
Patisiran’s impact on mNIS+7 was irrespective of concomitant tafamidis or diflunisal use, sex, or age. Clinical
assessments of motor function, autonomic symptoms, disease stage, and quality of life remained stable over
24 months. No significant changes were observed for echocardiographic measures or cardiac biomarkers in the
cardiac subgroup. Exploratory analyses demonstrated improvements in nerve-fiber density with corresponding
reductions in amyloid burden observed in skin biopsies over 24 months.
Conclusions: Long-term treatment with patisiran had an acceptable safety profile and was associated with halting/
improvement of polyneuropathy progression in patients with hATTR amyloidosis.
Trial registration: The study was registered at ClinicalTrials.gov (identifier: NCT01961921) on October 14, 2013.
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Hereditary transthyretin-mediated (hATTR) amyloidosis is
a progressive and life-threatening disease caused by muta-
tions in the gene encoding the transthyretin (TTR) protein
[1, 2]. TTR circulates as a tetrameric protein produced pre-
dominantly by the liver [3], with its primary role transport-
ing vitamin A complexed with retinol-binding protein
(RBP), with a minor role as a thyroxine carrier [4]. Over
120 TTR mutations confer amyloidogenicity [5], resulting
in the accumulation of misfolded TTR protein as amyloid
fibrils in multiple sites including nerves, heart, gastrointes-
tinal tract, eye, and central nervous system [6, 7]. This
pathophysiology leads to a heterogeneous clinical presenta-
tion that includes sensory and motor, autonomic, and car-
diac symptoms, with the majority of patients displaying a
mixed phenotype of both polyneuropathy and cardiomyop-
athy [8–11]. hATTR amyloidosis is associated with signifi-
cant morbidity and mortality, with a median survival
of 4.7 years following diagnosis [12]. The presence of car-
diac involvement is associated with a worse prognosis with
a reduced survival (3.4 years) reported in these patients [13].
A substantial decline in quality of life (QOL) and physical
functioning is observed as hATTR amyloidosis progresses,
reflecting disease involvement across multiple systems.
Thus, there is a need for treatments that target the patho-
genic TTR protein, rather than the symptoms associated
with specific tissues. Current treatment strategies for
hATTR amyloidosis directed at disease pathophysiology in-
clude prevention of TTR protein production or stabilization
of the TTR protein complex. Orthotopic liver transplant-
ation (OLT), which replaces the source of mutant TTR, has
been mainly used in patients with early-stage polyneurop-
athy without cardiac involvement [14]; however, this strat-
egy has been utilized much less in recent years after the
introduction of medical therapy [14]. OLT also does not
prevent deposition of wild-type (wt) TTR protein, which
contributes to subsequent disease progression in post-OLT
patients [15]. Treatment with TTR tetramer stabilizers
(tafamidis: approved in EU and select regions for treatment
of the polyneuropathy of hATTR amyloidosis [16]; and
diflunisal: used off-label for hATTR amyloidosis [6]) has
been shown to slow progression of neurologic impairment
[17, 18]. Additionally, a recent Phase III study of tafamidis
showing reduced cardiovascular mortality and hospitaliza-
tions in patients with ATTR amyloidosis with cardiomyop-
athy resulted in USA and EU approval for the treatment of
the cardiomyopathy of ATTR amyloidosis derived from wt
or mutant TTR for early-stage disease [19]. Inotersen, an
antisense oligonucleotide which reduces circulating TTR
levels, is approved in the USA and EU for the treatment of
the polyneuropathy associated with hATTR amyloidosis
[11]. While these treatments may slow the natural progres-
sion of hATTR amyloidosis, worsening of neurologic and/or
cardiac function is observed in the majority of patients.Patisiran is an RNA interference (RNAi) therapeutic
that targets both wt and mutant TTR mRNA, thereby re-
ducing expression of all forms of TTR protein. Patisiran
is formulated in a lipid nanoparticle facilitating delivery
to the liver, which is the primary site of TTR production
[3, 20]. Across the clinical development program, pati-
siran has demonstrated robust, rapid, and sustained re-
duction of TTR in patients with hATTR amyloidosis
[10, 20, 21]. In the recent Phase III APOLLO study,
18 months of patisiran dosing demonstrated the po-
tential to halt or reverse polyneuropathy and improve
QOL from baseline in the majority of patients [10],
leading to the approval of patisiran in the USA and
several other countries for the treatment of hATTR
amyloidosis with polyneuropathy [22, 23]. Patisiran
also improved exploratory measures of cardiac structure
and function compared with placebo in a pre-specified
analysis of patients with cardiac involvement in the
APOLLO study [24]. Here, we report the results from an
open-label extension (OLE) of a Phase II study of patisiran
in patients with hATTR amyloidosis with polyneuropathy.
Safety, efficacy, and pharmacodynamic (PD) data are de-
scribed over 24months, which is, to date, the longest
completed clinical trial with patisiran.Methods
Study design and participants
This was a multicenter, international, Phase II OLE study
of patisiran conducted across seven countries: USA, Brazil,
France, Germany, Portugal, Spain, and Sweden. Eligible
patients had biopsy-proven hATTR amyloidosis with evi-
dence of mild-to-moderate neuropathy, and had previ-
ously received and tolerated patisiran in the Phase II study
(NCT01617967) [21]. Patients had Karnofsky Performance
Status ≥60%; adequate liver and renal function; absolute
neutrophil count ≥1500 cells/mm3; platelet count ≥100,000
cells/mm3; and hemoglobin ≥100 g/l. Key exclusion criteria
included: prior OLT; unstable angina or uncontrolled car-
diac arrhythmia; and New York Heart Association heart
failure class > II. Patients who received an investigational
drug other than tafamidis or diflunisal within 30 days of
the patisiran first dose were also excluded. Further details
on inclusion/exclusion criteria are in Additional file 1:
Supplementary methods.
This study was conducted according to the guidelines
of the International Conference on Harmonisation, the
World Health Organization Declaration of Helsinki, and
the Health Insurance Portability and Accountability Act
of 1996. Written informed consent was obtained from
all participants in the study. The study protocol was ap-
proved by local Institutional Review Boards and Ethics
Committees, and all subsequent protocol amendments
underwent the same approval procedure.
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Patients received intravenous infusions of patisiran
0.3 mg/kg (over 70min) every 3 weeks for approximately
2 years. Patients received a premedication (dexametha-
sone, paracetamol/acetaminophen, H1 and H2 blockers, or
equivalent) to reduce the likelihood of an infusion-related
reaction (IRR). An oral daily supplemental dose of vitamin
A was also given. Patients were monitored before the first
dose (Day − 28 to Day 0), during dosing (Day 0 to Day
735), and at follow-up (Day 756 and 791). Safety was eval-
uated throughout the study, and included vital signs, phys-
ical and ophthalmologic examinations, clinical laboratory
tests, electrocardiograms, and adverse event (AE) moni-
toring. AEs were categorized by the Investigators as either
mild, moderate or severe, and coded according to the
Medical Dictionary for Regulatory Activities (MedDRA®)
version 18.0.
Serum TTR concentration was assessed using both
enzyme-linked immunosorbent assays and turbidimetric as-
says. Serum RBP was quantified using nephelometry and
serum vitamin A was quantified using a high-performance
liquid chromatography assay. Details of assessment timings
are in Additional file 1: Supplementary methods.
Neurologic function was assessed using the modified
Neuropathy Impairment Score +7 (mNIS+7), Neuropathy
Impairment Score +7 (NIS+7), and Neuropathy Impair-
ment Score (NIS), at baseline and every 6months thereafter
[25]. To standardize the efficacy assessment and minimize
variability across the multiple study centers, neurologists
were trained to perform the mNIS+7 evaluation at a central
center (Dyck Peripheral Nerve Research Laboratory, Mayo
Clinic, Rochester, MN, USA). QOL, disability, motor func-
tion, nutritional status, autonomic symptoms, and disease
stage (outlined in Outcomes below) were assessed at base-
line and every 6months thereafter (details in Additional file
1: Supplementary methods). Measurements were based on
two independent readings taken at least 24 h (but no
greater than 7 days) apart and performed by the same in-
vestigator when possible. Tandem skin punch biopsies of
the distal thigh and distal leg were obtained at baseline and
every 6months thereafter (patient status allowing). These
biopsies were used to quantify intra-epidermal nerve-fiber
density (IENFD; sensory innervation) and sweat gland
nerve-fiber density (SGNFD; autonomic innervation) based
on blinded central analysis. Congo Red staining was used to
serially assess dermal amyloid burden in the biopsies.
In a subgroup of patients with baseline cardiac involve-
ment (cardiac subgroup; defined as left ventricular [LV]
wall thickness of ≥13mm on echocardiogram in the ab-
sence of hypertension, controlled hypertension, or aortic
valve disease), serial echocardiograms were performed every
6months and blood samples were taken every 3months for
central assessment of the cardiac biomarkers troponin I
and N-terminal pro-brain natriuretic peptide.Outcomes
The primary objective was to evaluate the safety and tol-
erability of long-term dosing with patisiran. Secondary
objectives were to assess the PD effect of long-term pati-
siran dosing on serum TTR levels, and to monitor
changes from baseline in the following measures [25]:
mNIS+7; QOL (EuroQoL 5-dimensions questionnaire);
disability (Rasch-built Overall Disability Scale [R-ODS]);
motor function (10-meter [m] walk test and dynamometric
grip strength); and nutritional status (modified body mass
index). Exploratory endpoints included evaluation of
changes in: NIS, NIS+7, familial amyloid polyneuropathy
(FAP) stage, polyneuropathy disability (PND) score; patient-
reported autonomic symptoms (Composite Autonomic
Symptom Score [COMPASS]-31 questionnaire); sensory
and autonomic innervation of the skin; dermal amyloid
burden [25]; and cardiac parameters (measured by echo-
cardiogram and circulating cardiac biomarkers) in patients
in the cardiac subgroup.
Statistical analysis
For each patient population analyzed in this OLE study,
categorical variables were calculated as the number and
percentages of patients; for continuous variables, mean,
median, standard deviation, and range were calculated.
Descriptive statistics provided for clinical laboratory tests,
vital signs, all clinical activity parameters, and echocardio-
grams were presented as actual values and changes from
baseline relative to each on-study observation.
This trial is registered with ClinicalTrials.gov, number
NCT01961921.
Results
A total of 27 of 29 patients from the Phase II study [21]
were enrolled in this OLE study (1 patient withdrew for
personal reasons, the other discontinued the Phase II
study due to AEs). The time between last patisiran dose
in the Phase II study and first dose in this OLE study
ranged from 169 to 512 days. Of the 27 patients enrolled,
25 completed the OLE study (completion date August
31, 2016); 1 patient withdrew after approximately
19months due to gastro-esophageal cancer (unlikely re-
lated to patisiran), which proved fatal, and 1 patient died
of a myocardial infarction (not related to patisiran) after
completing all dosing but before the end of the study.
Median treatment duration was 25 months (range,
19–25 months), with a median of 35 doses (range,
27–36 doses) administered per patient.
Baseline clinical characteristics of the OLE population are
shown in Table 1. At study entry, 12 patients (44%) had
ambulatory difficulties due to neuropathy (PND score > I),
and 20 (74%) and 14 (52%) had a medical history of gastro-
intestinal or renal and urinary disorders, respectively.
Twenty patients (74%) were receiving TTR tetramer
Table 1 Patient baseline demographics and disease
characteristics
Characteristic Total population (n = 27)



















mNIS+7 (max. impairment: 304) 53.0 (2.0 to 122.5)
NIS (max. impairment: 244) 34.8 (4.0 to 93.4)
mBMI, (kg/m2 × g/L) 1030.5 (728.6 to 1379.6)
EQ-5D (max. impairment: 0) 0.8 (0.3 to 1.0)
Cardiac subgroup 11 (41%)
Val30Met/non-Val30Metb, n 8/3
NT-proBNP (pg/mL)c 809.8 (105.0 to 2070.0)
Troponin I (ng/mL)d 0.14 (0.03 to 0.69)
LV wall thickness (cm) 1.6 (1.3 to 1.9)
Abbreviations: EQ-5D EuroQoL 5-dimensions questionnaire, FAP familial
amyloid polyneuropathy, LV left ventricular, mBMI modified body mass index,
mNIS+7 modified Neuropathy Impairment Score + 7, NIS Neuropathy
Impairment Score, NT-proBNP N-terminal pro-brain natriuretic peptide, PND
polyneuropathy disability, QOL quality of life, TTR transthyretin. All data are
mean (range) or n (%), unless otherwise stated
aNon-Val30Met mutations: Ser77Tyr (n = 2), Ser77Phe (n = 2), Tyr116Ser (n = 1),
Phe64Leu (n = 1), Arg54Thr (n = 1)
bNon-Val30Met mutations in cardiac subgroup: Arg54Thr (n = 1), Ser77Phe
(n = 1), Ser77Tyr (n = 1)
cNT-proBNP normal range is: ≤ 97 pg/mL (age 18–45); ≤ 121 pg/mL (age 45–55);
≤ 198 pg/mL (age 55–65); ≤ 285 pg/mL (age 65–75); ≤ 526 pg/mL (age ≥ 75)
dTroponin I normal range is: < 0.03 ng/mL
Table 2 Summary of safety data
AE Total population (n = 27) n (%)
Summary of AEs
Any AE 26 (96)
Any AE related to study drug 16 (59)
Any serious AE 7 (26)
Any study drug-related serious AE 0
Death 2 (7)
Any AE leading to discontinuation 2 (7)
Common AEs (occurring in > 15% of patients)
Flushing 7 (26)
Diarrhea 6 (22)
Infusion-related reaction 6 (22)
Nasopharyngitis 6 (22)




AEs related to study drug in > 2 patients
Infusion-related reaction 6 (22)
Flushing 6 (22)
Diarrhea 3 (11)
Abbreviation: AE adverse event
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stabilizer use (diflunisal [n = 5]; tafamidis [n = 1]) be-
tween 1 and 18months after entering the study. Eleven
patients were included in the cardiac subgroup, for whom
the mean LV wall thickness was 1.6 cm (range, 1.3–1.9
cm) (Table 1).
Overall, 26 patients (96%) reported AEs (Table 2), the
majority of which were mild or moderate in intensity.AEs potentially related to patisiran occurred in 16 (59%)
patients. No patient discontinued the study due to a
drug-related AE. The most common drug-related AEs
were mild flushing and IRRs (6 patients [22%] each).
The incidence and number of IRRs decreased over time;
all IRRs were mild in severity. All patients received their
complete dose of patisiran, but 2 patients had temporary
infusion interruptions due to IRRs. In 1 patient, the infu-
sion rate was slowed with no subsequent IRRs; the other
patient had mild local intravenous site irritation.
Serious AEs were reported in 7 patients (26%), none of
which were considered related to patisiran (Table 2). Of
the serious AEs, only osteonecrosis (n = 2) was reported in
more than 1 patient (Additional file 2: Table S1). Severe
AEs were reported in 5 patients, with none considered re-
lated to patisiran; all severe events were also serious AEs.
Two patients died during the study, following cessation of
patisiran treatment, as detailed above. There were no clin-
ically significant changes related to patisiran in liver func-
tion tests, renal function, thyroid function, or hematologic
parameters (including platelet count), and no clinical
manifestations of vitamin A deficiency. There were no
clinically relevant changes in vital signs, electrocardiogram
parameters, or ophthalmology tests. The overall safety
profile of patisiran was similar in the cardiac subgroup
(Additional file 3: Table S2) compared with the overall
study population, and similar irrespective of concomitant
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sal) (data not shown). Furthermore, the overall safety pro-
files of concomitant treatment with either patisiran and
tafamidis (median exposure 736 days [range: 19–747 days])
or patisiran and diflunisal (median exposure 421 days
[range: 139–736 days]) in small cohorts of patients
were consistent with the safety profiles of the respective
therapies as monotherapies [17, 18].
Serum TTR reduction was rapid and robust following
the first dose of patisiran, with mean reduction from
baseline nearing 80% by Day 18 (Fig. 1). A sustained
mean reduction of 82% was achieved over 24 months,
with mean maximal reduction of 93%. The magnitude
and dynamics of TTR reduction were similar between
patients who received patisiran and TTR stabilizers com-
pared with patisiran alone (Additional file 4: Table S3).
Similarly, TTR genotype (Val30Met versus non-
Val30Met), sex, and age (< 65 versus ≥65 years) did not
affect the PD activity of patisiran (Additional file 4:
Table S3). Overall, serum vitamin A and RBP levels were
reduced by > 65% after 24 months of treatment, as ex-
pected based on the known role of TTR in binding and
transport of the RBP–vitamin A complex [26].
At 24 months, there was a mean mNIS+7 decrease
(improvement) from baseline of 6.95 points (Table 3;
Fig. 2); 19 patients (70.4%) had an improvement (de-
crease from baseline at 24 months) in mNIS+7 score. Al-
though patisiran appeared to affect all components of
mNIS+7 in a similar manner directionally, sensory mea-
sures exhibited the greatest decrease from baseline (im-
provement) at 24 months by quantitative sensory testing
(Table 3). The mean change in mNIS+7 was similar ac-
cording to TTR tetramer stabilizer use, sex, and inFig. 1 Serum TTR reduction. Percentage change in serum TTR from baselin
indicated on the graph with an x. BSL, baseline; ELISA, enzyme-linked immpatients < 65 or ≥ 65 years old (Table 3). The mean change
(standard error of the mean) in NIS and NIS +7 from
baseline at 24months was + 1.92 (1.84) and + 2.54 (1.84)
points, respectively (Additional file 5: Fig. S1a and b).
Multiple additional clinical parameters, including
EuroQoL 5-dimensions questionnaire, R-ODS, 10-m
walk distance, hand grip strength, and COMPASS-31
score, showed stability throughout the 24-month treat-
ment period (Table 4). Within the cardiac subgroup,
echocardiographic assessments and serum biomarker
levels also remained stable (Table 4). The majority of pa-
tients showed stabilization of FAP stage (20 [74%] pa-
tients with no change in FAP stage at 24 months) or
PND score (23 [85%] patients with no change in PND
score at 24 months) (Additional file 6: Table S4).
Exploratory analyses evaluating SGNFD of the lower limb
demonstrated increased fiber density in the distal thigh at
6, 12, 18, and 24months, and in the distal leg at 24months
(p < 0.05) (Fig. 3a and b). Conversely, a decrease (p < 0.05)
in dermal amyloid burden was demonstrated in both distal
thigh and distal leg over 24months (Fig. 3c). IENFD
remained stable over time (data not shown).Discussion
This OLE study evaluated the safety, PD, and clinical ef-
fect of patisiran on patients with hATTR amyloidosis
with polyneuropathy over 24 months. Patisiran, dosed
once every 3 weeks at 0.3 mg/kg, induced rapid and ro-
bust TTR reduction in serum. A mean reduction of ap-
proximately 82% was sustained across the 24-month
treatment period, consistent with the median 81% TTR
reduction reported at 18 months in the Phase IIIe over time. Pre- and post-dose (0.3 mg/kg Q3W patisiran) values are
unosorbent assay; Q3W, every 3 weeks; TTR, transthyretin
Table 3 Change in mNIS+7 by components and subgroups at 24 months of patisiran treatment
Change from baseline to Month 24
n Mean (SEM) Median (range)
mNIS+7 component
Total 26 −6.95 (2.03) −7.00 (−34.63 to 15.38)
NIS-Weakness 26 1.23 (1.43) 0.00 (−13.50 to 24.38)
NIS-Reflexes 26 −0.48 (0.53) 0.00 (−6.00 to 7.00)
QST 26 −7.4 (2.04) −6.0 (−40.0 to 16.0)
NCS ∑5 26 −0.19 (0.18) −0.25 (−2.00 to 2.50)
Postural BP 26 −0.10 (0.06) 0.00 (−1.00 to 0.50)
mNIS+7 by TTR tetramer stabilizer use
Patisiran alone 7 −6.75 (5.24) −8.50 (−28.50 to 15.38)
Patisiran + TTR tetramer stabilizer 19 −7.03 (2.11) −6.63 (−34.63 to 3.88)
Abbreviations: BP blood pressure, mNIS+7 modified Neuropathy Impairment Score +7, NCS nerve conduction studies, NIS Neuropathy Impairment Score, QST
quantitative sensory testing, SEM standard error of the mean, TTR transthyretin
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axis of any PD effect with chronic dosing.
In this study, patisiran was generally well tolerated, with
the majority of AEs mild to moderate in intensity, and no
patient discontinued treatment due to a patisiran-related
AE. Mild IRRs were among the most common drug-
related AEs (23%), yet they did not interfere with the com-
pletion of dosing, and decreased in incidence over time.
No clinically relevant changes in laboratory values related
to patisiran, including indicators of liver or kidney func-
tion, were observed during the study. In addition, there
were no safety signals regarding thrombocytopenia with
patisiran [27]. The expected reduction in serum vitamin AFig. 2 Mean change from baseline (SEM) in mNIS+7 in the all-treated popu
modified Neuropathy Impairment Score +7; SEM, standard error of the mealevels that accompanied TTR suppression was not associ-
ated with any clinical manifestations of vitamin A defi-
ciency (e.g. ocular events), which is possibly due to
redundant mechanisms for its transport and tissue uptake
[28]. The overall safety profile is consistent with that ob-
served in the APOLLO study [10], with no new safety sig-
nals reported with 24 months of patisiran dosing.
Furthermore, the safety data in the cardiac subgroup in
this study were similar to that observed in the overall
population, and with that observed in patients in the car-
diac subpopulation in the APOLLO study. Patisiran also
had an acceptable safety profile in patients with renal
amyloid involvement at baseline, and in patients takinglation over 24months. Error bars represent the SEM. mNIS+7,
n
Table 4 Changes in clinical assessments at 24 months with
patisiran treatment
Assessment Change from baseline to
Month 24
n Mean (SEM)
EQ-5D (max. impairment: 0) 26 −0.01 (0.02)
R-ODS (no limitations: 48) 25 −1.8 (0.8)
10-m walk (m/s) 21 0.03 (0.04)
Hand grip strength (kg) 26 1.5 (1.2)
mBMI (kg/m2 × g/L) 22 −60.8 (34.9)
COMPASS-31 (max. impairment: 100) 26 1.3 (1.8)
Cardiac subgroup (n = 11)
NT-proBNP (pg/mL) 8 −49.6 (170.8)
Troponin I (ng/mL) 8 −0.1 (0.1)
LV mass (g) 10 −16.7 (11.7)
LV wall thickness (cm) 10 −0.08 (0.1)
Ejection fraction (%) 10 −0.6 (1.5)
Peak longitudinal strain (%) 10 0.9 (0.9)
10-m walk (m/s) 7 0.03 (0.05)
Abbreviations: EQ-5D EuroQoL 5-dimensions questionnaire, COMPASS
Composite Autonomic Symptom Score, LV left ventricular, m meter, mBMI
modified body mass index, NT-proBNP N-terminal pro-brain natriuretic peptide,
QOL quality of life, R-ODS Rasch-built Overall Disability Scale
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siran to treat a diverse patient population.
The polyneuropathy seen in symptomatic patients with
hATTR amyloidosis is rapidly progressive [29]. While pa-
tients with diabetic polyneuropathy exhibit a < 1-point/year
increase in NIS-Lower Limbs [30], patients with hATTR
amyloidosis and a baseline NIS similar to that in the
current study have an estimated 26-point increase in
mNIS+7 after 24 months [31]. Indeed, patients in the
APOLLO placebo arm demonstrated a 28-point increase in
mNIS+7 over 18 months, highlighting the urgency to treat
patients with hATTR amyloidosis as early in the disease
course as possible [10]. Although the current study did not
have a comparator arm, the mean 6.95-point improvement
in mNIS+7 at 24 months contrasts markedly from the
expected worsening without active treatment. Notably,
the magnitude of mNIS+7 score improvement in this
study is similar to that observed following 18 months
of patisiran treatment in APOLLO (6.0-point im-
provement), supporting the consistent effects of pati-
siran on polyneuropathy. In this study, these data
indicate that patisiran can halt or reverse neuropathy,
as 19 of 27 patients showed a decrease from baseline
in mNIS+7 at 24 months, demonstrating a reversal in
polyneuropathy manifestations in the majority of pa-
tients. Similarly, in the APOLLO study the majority
of patients demonstrated an improvement in mNIS+7
score compared with baseline [10].These data are consistent with those reported in APOLLO
and compare favorably to those reported for other TTR sta-
bilizing or reduction therapies [11, 17, 18, 32, 33] in patients
with hATTR amyloidosis with polyneuropathy. It should be
noted that measures of neurologic impairment have varied
across studies of different therapeutic agents. The mNIS+7
scale was used in this study and APOLLO [25] to fully assess
the progression of this polyneuropathy. The mNIS+7 scale
includes measures of autonomic function and nerve conduc-
tion that are not captured in the NIS score [34]. Notably,
the mNIS+7 utilizes smart somatotopic quantitative sensa-
tion testing to provide a better balance between measure-
ment of large and small sensory fibers, and to measure
sensation loss across the body [34]. The mNIS+7 scale thus
represents a disease-specific measure of polyneuropathy in
hATTR amyloidosis, supporting its use as the primary end-
point in recent pivotal studies [10, 11]. In the current study,
a consistent, favorable effect on mNIS+7 was observed irre-
spective of age at onset or mutation status, as was also ob-
served in APOLLO [10].
It should be noted that there was concomitant use of
either tafamidis or diflunisal in 20 of 27 patients at base-
line. Irrespective of this concomitant TTR tetramer
stabilizer use, patisiran was shown to have a similar ef-
fect on mNIS+7; notably, the 6 patients who discontin-
ued their stabilizer within 18 months did not exhibit
neurologic disease progression.
The decrease in mNIS+7 over 24 months supports the
hypothesis that patisiran has the potential to alter the
course of hATTR amyloidosis with polyneuropathy. The
exploratory findings in autonomic nerve-fiber regener-
ation and amyloid regression in this study may also
highlight a potential effect of patisiran on disease patho-
physiology. However, it should be noted that these were
exploratory analyses, and that there are currently no nat-
ural history data to contextualize the impact of patisiran
on nerve-fiber regeneration.
Multiple additional clinical measures stabilized over
24 months, and indeed all measures, whether based
on neurologists’ assessments (mNIS+7), patient-based
performance (timed 10-m walk), or blinded assessment of
pathologic samples (skin biopsy), were similar or im-
proved at 24 months compared with baseline. Addition-
ally, stable COMPASS-31 autonomic symptom scores
over the course of the OLE support a stabilizing effect of
patisiran on hATTR amyloidosis-related autonomic dys-
function, which is known to impart a substantial disease
burden in hATTR amyloidosis. Notably, measures of
cardiac structure and function were generally unchanged
after 24 months of patisiran dosing in patients with car-
diac involvement, contrasting to the worsening of these
parameters observed without active treatment. The
improvements to neuropathy measures in the cardiac
subgroup observed in this study further support the
Fig. 3 Change in sweat gland nerve-fiber density and dermal amyloid burden of the lower limb. a Change in sweat gland nerve-fiber density in
distal thigh and distal leg to 24months. b Distal thigh sweat gland innervation at baseline and at Month 24 in an individual patient, with nerve
fibers immunostained for PGP 9·5 (green), blood vessels immunostained for CD31 (red), and cell nuclei labeled with DAPI (blue). c Change from
baseline to 24 months in amyloid burden for the lower limb. The statistical significance (performed as a post hoc analysis) of the change from
baseline is shown for each time-point where: *p = 0.01–0.05, **p = 0.001–0.01. BSL, baseline; CD31, cluster of differentiation 31 protein (or platelet
endothelial cell adhesion molecule [PECAM1]); DAPI, 4′,6-diamidino-2-phenylindole; PGP, protein gene product
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phenotype, which was also observed in the APOLLO
study [10, 24].
The beneficial effect and tolerability of patisiran treat-
ment, reported here and in the APOLLO study, demon-
strate the clinical impact of reducing TTR in patients with
hATTR amyloidosis. This extended experience, coupled
with secondary analyses of the APOLLO data suggesting
benefits in a cardiac subpopulation [24], support examin-
ing the effect of patisiran on patients with ATTR amyloid-
osis with cardiomyopathy (APOLLO-B trial [NCT039973
83]) and the development of the investigational RNAi
therapeutic vutrisiran. The vutrisiran siRNA utilizes next-
generation enhanced stabilization chemistry (ESC), and is
conjugated to a trivalent GalNAc ligand to ensure hepatic
delivery [35]. The ESC platform is designed for increased
potency and high metabolic stability, allowing for a quar-
terly subcutaneously administered injection that does notrequire premedication. Expanding the potential range of
pharmacotherapies for ATTR amyloidosis will provide
greater treatment choice, allowing physicans and patients
to select the option most appropriate for this debilitating
disease.
Conclusions
In summary, these results demonstrate that long-term
treatment with patisiran had an acceptable benefit:risk
profile, and provide further data that it may halt or re-
verse neuropathy progression as well as have beneficial
effects on QOL, physical functioning, autonomic symp-
toms, and activities of daily living by reducing TTR
levels. The safety and efficacy of patisiran is consistent
with that reported in APOLLO (NCT01960348), the lar-
gest Phase III clinical study to enroll patients with
hATTR amyloidosis with polyneuropathy [10]. These
data resulted in the approval of patisiran in select
Coelho et al. Orphanet Journal of Rare Diseases          (2020) 15:179 Page 9 of 10countries globally for the treatment of hATTR amyloid-
osis with polyneuropathy. All 25 eligible patients from
this Phase II OLE study have since enrolled in the pati-
siran Global OLE study (NCT02510261), which will con-
tinue to collect long-term safety and efficacy data for an
additional 5 years.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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